Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

In February, it announced a collaboration with California’s Gilead Sciences to develop the cancer drug Trodelvy in a deal worth up to $210mn. Trodelvy is already approved to treat some cancers ...

US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...

The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.

Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...